Therapeutic hemapheresis practitioners need to know about the treatment of thrombotic thrombocytopenic purpura

Transfusion and Apheresis Science

Volumn 28, Issue 3, 2003, Pages 215-217

  Golden, Patricia Jost ^a  

^a Hemapheresis Consultant   (United States)

Author keywords

Apheresis; Apheresis operator; Education; Plasma exchange; TTP

Indexed keywords

APHERESIS; ARTICLE; CONTINUING EDUCATION; HUMAN; MORTALITY; PATHOPHYSIOLOGY; PHYSICIAN; PLASMAPHERESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0037410055     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00053-3     Document Type: Article

References (17)

1. Moschowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc. NY Pathol. Soc. 24:1924;21-24.
2. McLeod B.C., Drew M.J. Apheresis: principles and practice. 1997;AABB Press, Bethesda, MD. p. 319-21.
3. Moake J.L. TTP - desperation, empiricism, progress. New Engl. J. Med. 325(6):1991;426-428.
4. Rock G.A., Shumak K.H., Buskard N.A.et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. New Engl. J. Med. 325:1991;393-397.
5. Bell W.R., Braine H.G., Ness P.M., Kickler T.S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. New Engl. J. Med. 325(6):1991;398-403.
6. Bennett C.L., Connors J.M., Carwile J.M.et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. New Engl. J. Med. 342(24):2000;1773-1777.
7. Creager A.J., Brecher M.E., Bandarenko N. Thrombotic thrombocytopenic purpura that is refractory in two patients with occult infection. Transfusion. 38:1998;419-423.
8. Rizvi M.A., Vesely S.K., George J.N.et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion. 40:2000;896-901.
9. Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-44.
10. Tsai H.-.M., Lian E.C.-.Y. Antibodies to von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. New Engl. J. Med. 339:1998;1578-1584.
11. Furlan M., Robles R., Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 87:1996;4223-4234.
12. Furlan M., Robles R., Galbusera M.et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 89:1997;3097-3103.
13. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96(4):1223-29.
14. Veyradier A, Obert B, Houllier A, Meyer D, Gima JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001;98(6):1765-72.
15. Furlan M.et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. New Engl. J. Med. 339(22):1998;1578-1584.
16. Kelton J.G. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: will recent insight into pathogenesis translate into better treatment. Transfusion. 42:2002;388-392.
17. Phatak D.R., Joseph J. A microscopic atlas of thrombotic thrombocytopenic purpura. Transfusion. 42:2002;387.